Nektar Chief R&D Officer sells 180 shares

NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade.

Accepted by SEC EDGAR 02/20/2026 - 07:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade. The weighted average sale price was $73.00 per share, and he held 21,174 shares directly after the transaction.

Insider Trade Summary

Net Seller: 180 shares

Net Sell 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Sold 180 shs ($13K)

Share of Position Sold 0.84%

Type	Security	Shares	Price	Value
Sale	Common Stock	180	$73.00	$13K

Holdings After Transaction: Common Stock — 21,174 shares (Direct)

Holdings Before and After: Common Stock, 21,354 to 21,174 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nektar Therapeutics (NKTR) disclose in this Form 4?

Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky sold 180 common shares on February 18, 2026, at a weighted average price of $73.00. The sale was made specifically to cover tax withholding obligations from vesting RSUs.

How many Nektar (NKTR) shares did Jonathan Zalevsky sell and at what price?

Jonathan Zalevsky sold 180 shares of Nektar Therapeutics common stock at a weighted average price of $73.00 per share. The trades occurred in multiple transactions within a price range from $72.51 to $74.00, according to the filing footnote.

Was the Nektar (NKTR) insider transaction a discretionary sale?

The Form 4 states the transaction was not a discretionary trade. Shares were sold solely to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs) held by Jonathan Zalevsky, rather than a voluntary decision to reduce his investment.

How many Nektar Therapeutics (NKTR) shares does Jonathan Zalevsky hold after this sale?

Following the tax-withholding sale, Jonathan Zalevsky directly owned 21,174 shares of Nektar Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct holdings after the 180-share sale.

What role does Jonathan Zalevsky hold at Nektar Therapeutics (NKTR)?

Jonathan Zalevsky is identified as the Chief R&D Officer of Nektar Therapeutics. His position as a senior officer makes his equity transactions subject to Form 4 reporting requirements, providing transparency into changes in his direct ownership of company stock.

How were the sale prices for the Nektar (NKTR) insider transaction determined?

The filing notes the transaction was executed in multiple trades between $72.51 and $74.00 per share. The reported $73.00 figure represents the weighted average sale price, and full breakdowns are available upon request from the SEC staff, issuer, or shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		180(1)	D	$73(2)	21,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.